Joining forces against cancer

September 17, 2008

In cancer therapy, the best results are often achieved by combining treatments such as chemotherapy, radiotherapy and surgery. This multidisciplinary approach is the focus of special symposia at the meetings of the European Society for Medical Oncology (ESMO) and the European Society for Therapeutic Radiology (ESTRO) taking place in Sweden this month.

"We are at a crucial moment in our fight against cancer," said ESMO President Prof. Jose Baselga. "We have never before made so much progress in our fight to eradicate cancer as a cause of death, and multidisciplinary treatment is a key factor in this success."

New data presented at the 33rd ESMO Congress, 12-16 September 2008, Stockholm, Sweden also highlight the benefits of combined treatments:

Phase II trial of pazopanib before surgery in early lung cancer

Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, US researchers report. In a phase II trial, 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumor size shrink by up to 85%.

"This is a positive result that will be explored further," said Prof. Nasser Altorki from Weil Medical College of Cornell University in New York. "To my knowledge, no other results on the effect of angiogenesis inhibitors in early stage operable lung cancer have been published. The results presented here with pazopanib indicate a highly active drug in this setting and further development in lung cancer is underway to fully understand the value of this drug in this disease."

Chemotherapy, radiotherapy and cetuximab in head and neck cancer

Treating locally advanced head and neck cancers with an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, has shown promise in a phase II trial, Italian researchers report.

Their trial in 45 patients combined chemotherapy with fluorouracil and carboplatin given on weeks 1, 4 and 7 of treatment, with radiotherapy administered daily on weeks 2-3, 5-6 and 8-10. Cetuximab was also added weekly. "Both complete response rate and long-term results compare favorably with the best reported in the literature," Dr. Marco Merlano from the S. Croce General Hospital in Cuneo reports. 30 patients experienced a skin toxicity that the authors attribute to an interaction between the treatments, and 2 patients died from toxicities, they report.

Zoledronic acid added to adjuvant endocrine therapy prevents breast cancer recurrences

One-third of breast cancer recurrences in pre-menopausal women can be prevented by adding zoldronic acid to treatment with endocrine therapy combined with anastrazole or tamoxifen.

These results, reported for the first time recently, show that "we can positively impact the fate of our cancer patients by influencing the microenvironment of micro-metastases by relatively simple means," says lead author Prof. Michael Gnant from the Medical University of Vienna.

The study results are included in the ESMO "Oncology Highlights" session in Stockholm. The findings will be expanded with new data from a multivariate analysis of the variables affecting disease-free and recurrence-free survival, Professor Gnant said.

European Society for Medical Oncology

---

---

	Chemotherapy and Radiation For Dummies by Alan P. Lyss (Author), Humberto Fagundes (Author), Patricia Corrigan (Author) An informative, compassionate guide for cancer patients and their loved onesEach year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed advice on how to alleviate and cope with side effects-which range from hair loss to nausea to anemia-and describes how good nutrition, meditation, support groups, and other techniques and resources can help in the recovery process.
	Bangers and Mash - How to take on throat cancer, chemotherapy, radiotherapy and win, with help from an NLP coach by Keith Hern (Author) What is it really like to hear the words "you have throat cancer"? In Bangers and Mash, food-and wine-loving photographer Keith Hern tells us with honesty and humour exactly what it's like. From the grim reality of chemotherapy and radiotherapy treatments to unexpected moments of real warmth and kindness from friends old and new, the fight to survive is vividly described. With the help of an NLP coach, Keith challenges the cancer head-on and emerges triumphant into a new, more colourful world. A powerfully uplifting read.
	Coping With Chemotherapy and Radiation Therapy: Everything You Need to Know by Daniel Cukier (Author) New advances in treatment offer cancer patients more options than ever before. Coping with Chemotherapy and Radiation is an accessible, accurate guide to the latest developments in radiation therapy and chemotherapy. You will find important information on how chemotherapy and radiation treatments work; what to expect from treatments, how to alleviate common side effects, and more.
	Managing the Side Effects of Chemotherapy and Radiation by Marilyn J. Dodd (Author)
	Chemotherapy and Radiotherapy of Gastrointestinal Tumors (Recent results in cancer research) by Klein (Author)
	Concepts in Cancer Care: A Practical Explanation of Radiotherapy and Chemotherapy for Primary Care Physicians by Jay Scott Cooper (Author)
	Combined Effects of Chemotherapy and Radiotherapy on Normal Tissue Tolerance (Frontiers of radiation therapy and oncology) (v. 13) by J. M. Vaeth (Editor)
	Radiotherapy/Chemotherapy Interactions in Cancer Therapy: Potential Benefits and Hazards in the Clinic, 26th Annual San Francisco Cancer Symposium, ... of Radiation Therapy and Oncology) (v. 26) by John L. Meyer (Editor), Jerome M. Vaeth (Editor) The combination of radiotherapy and chemotherapy in cancer treatment creates a vast new dimension of both complexity and opportunity. This publication presents the pioneering work of many of the world's foremost authorities in this area and provides a broad insight into clinical experiences to date. The chapters in the first section discuss the interaction of chemotherapeutic agents and radiation as well as the potential for therapeutic gain from combined-modality treatment. In the second section, clinical chapters describe the possible benefits and hazards of radiotherapy/chemotherapy interaction in the important pursuit of local tumour control.
	Secondary Neoplasias Following Chemotherapy, Radiotherapy and Immunosuppression: Secondary Neoplasias After Organ Transplants and Radiotherapy (Contributions to Oncology, 55) by W. Queisser (Editor), W. Scheithauer (Editor), U. Ruther (Editor), C. Nunnensiek (Editor), H. J. Schmoll (Editor) Complete remissions and survival times of tumor patients are increasing steadily - and so is the risk of developing therapy-associated secondary malignancy. At the same time, we face the growing diagnostic and therapeutic problem of tumorigenesis during posttransplantation immunosuppressive therapy. The theoretical section delves into the various causes of tumorigenesis, with special chapters on secondary chemo- and/or radiotherapy-induced tumorigenesis and neoplasia occurring during posttransplantation immunosuppressive therapy. The risk of individual cytostatic agents causing secondary malignoma is covered, as are the functions and dysfunctions of immunosurveillance. The immune system's methods of recognizing tumors are also examined, and specific information on the role of...
	The Treatment of Cancer with Special Reference to Radiotherapy and Chemotherapy by J. S.(Editor) Mitchell (Author)